CTLA4 and lymphoma: Immune checkpoint inhibitors targeting the co-inhibitory molecules cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1 have been approved for the treatment of various solid tumors and lymphoma (72).